Monoclonal antibodies that recognize the native human thyrotropin receptor

AP Johnstone, JC Cridland, CR DaCosta… - Molecular and cellular …, 1994 - Elsevier
AP Johnstone, JC Cridland, CR DaCosta, E Harfst, PS Shepherd
Molecular and cellular endocrinology, 1994Elsevier
Monoclonal antibodies have been produced that recognize the native human thyrotropin
receptor by using a sensitive screening protocol based on flow cytofluorimetry combined
with recombinant eukaryotic cells expressing high levels of the full-length functional
receptor. The more standard screening method of ELISA preferentially selected antibodies
that only reacted with the denatured receptor. Mice were immunized with recombinant
receptor produced in either eukaryotic or prokaryotic systems; after screening and cloning …
Abstract
Monoclonal antibodies have been produced that recognize the native human thyrotropin receptor by using a sensitive screening protocol based on flow cytofluorimetry combined with recombinant eukaryotic cells expressing high levels of the full-length functional receptor. The more standard screening method of ELISA preferentially selected antibodies that only reacted with the denatured receptor. Mice were immunized with recombinant receptor produced in either eukaryotic or prokaryotic systems; after screening and cloning, three stable hybridoma lines were established. An IgM antibody (7B5) produced in response to the eukaryotic material recognized only the native receptor (by flow cytofluorimetry) and did not react with denatured material on ELISA or immunoblotting, suggesting that its epitope is conformational. In contrast, two IgGl antibodies (2C11 and 3B12) produced in response to the prokaryotic material recognized both native and denatured receptor (by flow cytofluorimetry, immunoprecipitation and immunoblotting). The use of different recombinant constructs in the immunoblotting procedure allowed the epitopes for both of the IgGl antibodies to be assigned to the region 125–369. None of the antibodies stimulated production of cAMP by recombinant cells expressing the full-length functional receptor, but one of the IgGl antibodies (2C11) did inhibit binding of radiolabelled thyrotropin to these same cells. These antibodies, and others that can now be produced with this screening protocol, will help define the relationship between structure and function of this important receptor.
Elsevier